These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 38436271

  • 1. Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
    Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, Seitzinger A, Guehring H, Shaw J, Tomic D, Hyvert Y, Harlow DE, Dyroff M, Wolinsky JS.
    Mult Scler; 2024 Apr; 30(4-5):558-570. PubMed ID: 38436271
    [Abstract] [Full Text] [Related]

  • 2. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
    Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS, Evobrutinib Phase 2 Study Group.
    N Engl J Med; 2019 Jun 20; 380(25):2406-2417. PubMed ID: 31075187
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
    Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D, evolutionRMS investigators.
    Lancet Neurol; 2024 Nov 20; 23(11):1119-1132. PubMed ID: 39307151
    [Abstract] [Full Text] [Related]

  • 4. Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
    Arnold DL, Elliott C, Martin EC, Hyvert Y, Tomic D, Montalban X.
    Neurology; 2024 Mar 12; 102(5):e208058. PubMed ID: 38335474
    [Abstract] [Full Text] [Related]

  • 5. Determination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis study.
    Papasouliotis O, Mitchell D, Girard P, Dangond F, Dyroff M.
    Clin Transl Sci; 2022 Dec 12; 15(12):2888-2898. PubMed ID: 36126241
    [Abstract] [Full Text] [Related]

  • 6. Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor.
    Bar-Or A, Cross AH, Cunningham AL, Hyvert Y, Seitzinger A, Gühring H, Drouin EE, Alexandri N, Tomic D, Montalban X.
    Mult Scler; 2023 Oct 12; 29(11-12):1471-1481. PubMed ID: 37626477
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
    Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A, Tolebrutinib Phase 2b Study Group.
    Lancet Neurol; 2021 Sep 12; 20(9):729-738. PubMed ID: 34418400
    [Abstract] [Full Text] [Related]

  • 8. Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis.
    Montalban X, Wallace D, Genovese MC, Tomic D, Parsons-Rich D, Le Bolay C, Kao AH, Guehring H.
    J Neurol Neurosurg Psychiatry; 2023 Jan 12; 94(1):1-9. PubMed ID: 36418156
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial.
    Wallace DJ, Dörner T, Pisetsky DS, Sanchez-Guerrero J, Patel AC, Parsons-Rich D, Le Bolay C, Drouin EE, Kao AH, Guehring H, Dall'Era M.
    ACR Open Rheumatol; 2023 Jan 12; 5(1):38-48. PubMed ID: 36530019
    [Abstract] [Full Text] [Related]

  • 10. Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants.
    Scheible H, Dyroff M, Seithel-Keuth A, Harrison-Moench E, Mammasse N, Port A, Bachmann A, Dong J, van Lier JJ, Tracewell W, Mitchell D.
    Clin Transl Sci; 2021 Nov 12; 14(6):2420-2430. PubMed ID: 34374206
    [Abstract] [Full Text] [Related]

  • 11. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
    Becker A, Martin EC, Mitchell DY, Grenningloh R, Bender AT, Laurent J, Mackenzie H, Johne A.
    Clin Transl Sci; 2020 Mar 12; 13(2):325-336. PubMed ID: 31654487
    [Abstract] [Full Text] [Related]

  • 12. Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis.
    Turner TJ, Brun P, Gruber RC, Ofengeim D.
    Drugs R D; 2024 Jun 12; 24(2):263-274. PubMed ID: 38965189
    [Abstract] [Full Text] [Related]

  • 13. Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants.
    Papasouliotis O, Mitchell D, Girard P, Dyroff M.
    Clin Transl Sci; 2022 Dec 12; 15(12):2899-2908. PubMed ID: 36165192
    [Abstract] [Full Text] [Related]

  • 14. Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective.
    Scheible H, Schieferstein H, Schmidt R, Pusecker K, Gradhand U, Gopalakrishnan S, Iqbal K, Dong J, Jones R, Meli C, Bolleddula J, Dyroff M, Georgi K.
    Xenobiotica; 2023 Dec 12; 53(8-9):547-558. PubMed ID: 37880944
    [Abstract] [Full Text] [Related]

  • 15. Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis.
    Steinmaurer A, Wimmer I, Berger T, Rommer PS, Sellner J.
    Curr Pharm Des; 2022 Dec 12; 28(6):437-444. PubMed ID: 34218776
    [Abstract] [Full Text] [Related]

  • 16. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS, Arnold DL, Brochet B, Hartung HP, Montalban X, Naismith RT, Manfrini M, Overell J, Koendgen H, Sauter A, Bennett I, Hubeaux S, Kappos L, Hauser SL.
    Lancet Neurol; 2020 Dec 12; 19(12):998-1009. PubMed ID: 33129442
    [Abstract] [Full Text] [Related]

  • 17. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004 Dec 12; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 18. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
    Caldwell RD, Qiu H, Askew BC, Bender AT, Brugger N, Camps M, Dhanabal M, Dutt V, Eichhorn T, Gardberg AS, Goutopoulos A, Grenningloh R, Head J, Healey B, Hodous BL, Huck BR, Johnson TL, Jones C, Jones RC, Mochalkin I, Morandi F, Nguyen N, Meyring M, Potnick JR, Santos DC, Schmidt R, Sherer B, Shutes A, Urbahns K, Follis AV, Wegener AA, Zimmerli SC, Liu-Bujalski L.
    J Med Chem; 2019 Sep 12; 62(17):7643-7655. PubMed ID: 31368705
    [Abstract] [Full Text] [Related]

  • 19. It is time to rethink clinical trials on Bruton's tyrosine kinase inhibitors in multiple sclerosis.
    Barboza A.
    Mult Scler Relat Disord; 2024 Feb 12; 82():105395. PubMed ID: 38184909
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T, Banwell B, Kappos L, Arnold DL, Gücüyener K, Deiva K, Skripchenko N, Cui LY, Saubadu S, Hu W, Benamor M, Le-Halpere A, Truffinet P, Tardieu M, TERIKIDS Investigators.
    Lancet Neurol; 2021 Dec 12; 20(12):1001-1011. PubMed ID: 34800398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.